tetano
Editor, Senior Moderator
Virol J
. 2023 May 3;20(1):85.
doi: 10.1186/s12985-023-02050-x. Differential abundance of IgG antibodies against the spike protein of SARS-CoV-2 and seasonal coronaviruses in patients with fatal COVID-19
Wouter L Smit[SUP] 1 2 [/SUP], Sophie van Tol[SUP] 3 [/SUP], Lenneke E M Haas[SUP] 4 [/SUP], Gijs J M Limonard[SUP] 5 [/SUP], Ailko Bossink[SUP] 5 [/SUP], Chantal Reusken[SUP] 3 [/SUP], Michiel Heron[SUP] 6 [/SUP], Steven F T Thijsen[SUP] 6 [/SUP]
Affiliations
Infection with the novel pandemic SARS-CoV-2 virus has been shown to elicit a cross-reactive immune response that could lead to a back-boost of memory recall to previously encountered seasonal (endemic) coronaviruses (eCoVs). Whether this response is associated with a fatal clinical outcome in patients with severe COVID-19 remains unclear. In a cohort of hospitalized patients, we have previously shown that heterologous immune responses to eCoVs can be detected in severe COVID-19. Here, we report that COVID-19 patients with fatal disease have decreased SARS-CoV-2 neutralizing antibody titers at hospital admission, which correlated with lower SARS-CoV-2 spike-specific IgG and was paralleled by a relative abundance of IgG against spike protein of eCoVs of the genus Betacoronavirus. Additional research is needed to assess if eCoV-specific back-boosted IgG is a bystander phenomenon in severe COVID-19, or a factor that influences the development of an efficient anti-viral immune response.
. 2023 May 3;20(1):85.
doi: 10.1186/s12985-023-02050-x. Differential abundance of IgG antibodies against the spike protein of SARS-CoV-2 and seasonal coronaviruses in patients with fatal COVID-19
Wouter L Smit[SUP] 1 2 [/SUP], Sophie van Tol[SUP] 3 [/SUP], Lenneke E M Haas[SUP] 4 [/SUP], Gijs J M Limonard[SUP] 5 [/SUP], Ailko Bossink[SUP] 5 [/SUP], Chantal Reusken[SUP] 3 [/SUP], Michiel Heron[SUP] 6 [/SUP], Steven F T Thijsen[SUP] 6 [/SUP]
Affiliations
- PMID: 37138352
- DOI: 10.1186/s12985-023-02050-x
Infection with the novel pandemic SARS-CoV-2 virus has been shown to elicit a cross-reactive immune response that could lead to a back-boost of memory recall to previously encountered seasonal (endemic) coronaviruses (eCoVs). Whether this response is associated with a fatal clinical outcome in patients with severe COVID-19 remains unclear. In a cohort of hospitalized patients, we have previously shown that heterologous immune responses to eCoVs can be detected in severe COVID-19. Here, we report that COVID-19 patients with fatal disease have decreased SARS-CoV-2 neutralizing antibody titers at hospital admission, which correlated with lower SARS-CoV-2 spike-specific IgG and was paralleled by a relative abundance of IgG against spike protein of eCoVs of the genus Betacoronavirus. Additional research is needed to assess if eCoV-specific back-boosted IgG is a bystander phenomenon in severe COVID-19, or a factor that influences the development of an efficient anti-viral immune response.